RASP (Actavia Life Sciences) 1-Year Sharpe Ratio: -1.05 (As of Jul. 12, 2026)


What is Actavia Life Sciences 1-Year Sharpe Ratio?

Actavia Life Sciences RASP -87.50% 1-Year Sharpe Ratio is -1.05 as of Jul. 12, 2026.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-12), Actavia Life Sciences's 1-Year Sharpe Ratio is -1.05.

Actavia Life Sciences  (OTCPK:RASP) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Actavia Life Sciences 1-Year Sharpe Ratio Related Terms

RASP vs BWV, FNCH, CWBR: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Actavia Life Sciences's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's 1-Year Sharpe Ratio falls into.


Actavia Life Sciences 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -1.05 mean?
Actavia Life Sciences (RASP) has a 1-Year Sharpe Ratio of -1.05 as of Jul. 12, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' 1-Year Sharpe Ratio too high?
Actavia Life Sciences' current 1-Year Sharpe Ratio is -1.05.
How does Actavia Life Sciences' 1-Year Sharpe Ratio compare to BWV and FNCH?
Actavia Life Sciences' 1-Year Sharpe Ratio of -1.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Actavia Life Sciences and its competitors. Actavia Life Sciences's current 1-Year Sharpe Ratio is -1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current 1-Year Sharpe Ratio of -1.05. The current 1-Year Sharpe Ratio is -1.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current 1-Year Sharpe Ratio is -1.05 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.